Exscientia (NASDAQ:EXAI) Trading 6.3% Higher

Exscientia plc (NASDAQ:EXAI)’s share price traded up 6.3% on Tuesday . The company traded as high as $4.62 and last traded at $4.53. 75,480 shares were traded during trading, a decline of 88% from the average session volume of 613,803 shares. The stock had previously closed at $4.26.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective on shares of Exscientia in a research report on Monday, April 22nd. Barclays cut their price objective on shares of Exscientia from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Monday, July 29th. Finally, TD Cowen assumed coverage on shares of Exscientia in a research report on Tuesday, July 9th. They issued a “buy” rating on the stock.

Exscientia Stock Performance

The firm has a market cap of $592.35 million, a P/E ratio of -3.56 and a beta of 0.85. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average is $5.26 and its two-hundred day moving average is $5.45.

Exscientia (NASDAQ:EXAI) last posted its earnings results on Tuesday, May 21st. The company reported ($0.21) EPS for the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. The firm had revenue of $6.70 million for the quarter. As a group, equities analysts predict that Exscientia plc will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Exscientia

Several hedge funds have recently modified their holdings of EXAI. GAMMA Investing LLC raised its holdings in shares of Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after purchasing an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after buying an additional 4,104 shares during the last quarter. Walled Lake Planning & Wealth Management LLC bought a new position in shares of Exscientia during the 4th quarter worth $64,000. New Republic Capital LLC bought a new position in shares of Exscientia during the 4th quarter worth $128,000. Finally, Private Advisor Group LLC grew its stake in shares of Exscientia by 114.3% during the 4th quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $144,000 after acquiring an additional 12,000 shares during the period. Institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.